Literature DB >> 15234290

Classification of Farnsworth-Munsell 100-hue test results in the early treatment diabetic retinopathy study.

Franca B Barton1, Donald S Fong, Genell L Knatterud.   

Abstract

PURPOSE: To classify and describe clinically meaningful classes of color vision defects using pretreatment Farnsworth-Munsell 100-hue results from the Early Treatment Diabetic Retinopathy Study (ETDRS) patients using standard statistical techniques.
DESIGN: The ETDRS was a randomized trial investigating retinal photocoagulation and oral aspirin in diabetic retinopathy.
METHODS: Farnsworth-Munsell (FM) 100-hue test was successfully administered before initiation of study treatment in each eye of 2701 of the 3711 ETDRS patients. Test results were converted into a Fourier series, classified by cluster analysis in the deferred-treatment group of eyes, and verified in the immediate-treatment group of eyes as separate samples.
RESULTS: Cluster analysis uncovered thirteen distinct patterns. Pattern A (51% or 1366 of the eyes) showed unimpaired hue discrimination and was comprised of younger patients with no or little macular edema. Pattern B eyes (10% or 262) showed generalized impairment of hue discrimination with no main axis defect. Patterns C (C1, C2, C3), comprising 26% (or 698) of the eyes, showed increasing severity of the yellow-blue diabetic retinopathy defect, associated with increasing mean age and increasing macular edema severity. Patterns D (D1, D2), comprising 6% (or 164) of the eyes, were similar to the C patterns but showed a stronger yellow-blue defect. Patterns E (E1, E2, E3), or approximately 2% (or 38) of the eyes and predominantly male, exhibited the expected pattern for congenital protan defect. Patterns F, G, and H, approximately 6% (or 153) of the eyes, showed distinct patterns of one-sided axes. The nomenclature is arbitrary.
CONCLUSIONS: Cluster analysis of FM 100-hue test results has found 13 patterns of impaired hue discrimination, helpful in understanding color vision defects in diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15234290     DOI: 10.1016/j.ajo.2004.02.009

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  9 in total

1.  New iPAD-based test for the detection of color vision deficiencies.

Authors:  Dolores de Fez; María José Luque; Lucía Matea; David P Piñero; Vicente J Camps
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-10-06       Impact factor: 3.117

2.  Localization and patterns of Cerebral dyschromatopsia: A study of subjects with prospagnosia.

Authors:  Daniel Moroz; Sherryse L Corrow; Jeffrey C Corrow; Alistair R S Barton; Brad Duchaine; Jason J S Barton
Journal:  Neuropsychologia       Date:  2016-06-14       Impact factor: 3.139

3.  Intravitreal pegaptanib sodium (Macugen®) for treatment of diabetic macular oedema: a morphologic and functional study.

Authors:  Michele Rinaldi; Flavia Chiosi; Roberto dell'Omo; Mario R Romano; Francesco Parmeggiani; Francesco Semeraro; Rodolfo Mastropasqua; Ciro Costagliola
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

4.  Effect of illumination on colour vision testing with Farnsworth-Munsell 100 hue test: customized colour vision booth versus room illumination.

Authors:  Kowser Zahiruddin; Shaj Banu; Ramya Dharmarajan; Vaitheeswaran Kulothungan; Deepa Vijayan; Rajiv Raman; Tarun Sharma
Journal:  Korean J Ophthalmol       Date:  2010-06-05

5.  Alterations of color vision and central visual field in patients with Vogt-Koyanagi-Harada syndrome.

Authors:  Peizeng Yang; Min Sun; Xiaoli Liu; Hongyan Zhou; Wang Fang; Li Wang; Aize Kijlstra
Journal:  J Ophthalmic Inflamm Infect       Date:  2012-02-02

6.  Quantitative computerized color vision testing in diabetic retinopathy: A possible screening tool?

Authors:  Rashid Al Saeidi; Marcus Kernt; Thomas C Kreutzer; Guenther Rudolph; Aljoscha S Neubauer; Christos Haritoglou
Journal:  Oman J Ophthalmol       Date:  2013-09

7.  Color vision abnormalities in type II diabetes: Sankara Nethralaya Diabetic Retinopathy Epidemiology and Molecular Genetics Study II report no 2.

Authors:  Laxmi Gella; Rajiv Raman; Vaitheeswaran Kulothungan; Swakshyar Saumya Pal; Suganeswari Ganesan; Sangeetha Srinivasan; Tarun Sharma
Journal:  Indian J Ophthalmol       Date:  2017-10       Impact factor: 1.848

8.  Acuity and colour vision changes post intravitreal dexamethasone implant injection in patients with diabetic macular oedema.

Authors:  Ahmed Abdel-Hay; Sobha Sivaprasad; Ahalya Subramanian; John L Barbur
Journal:  PLoS One       Date:  2018-06-26       Impact factor: 3.240

9.  Influence of retinopathy on the achromatic and chromatic vision of patients with type 2 diabetes.

Authors:  Luciana Cristina O Andrade; Givago S Souza; Eliza Maria C B Lacerda; Maira Tst Nazima; Anderson R Rodrigues; Liudmila M Otero; Francineide Ps Pena; Luiz Carlos L Silveira; Maria Izabel T Côrtes
Journal:  BMC Ophthalmol       Date:  2014-08-31       Impact factor: 2.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.